{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:20:20Z","timestamp":1783970420794,"version":"3.55.0"},"reference-count":22,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Recent findings on the biological activity of thiazolidin-4-ones and taking into account the lack of effective drugs used in the treatment of toxoplasmosis, their numerous side effects, as well as the problem of drug resistance of parasites prompted us to look for new agents. We designed and synthesized a series of new thiazolidin-4-one derivatives through a two-step reaction between 4-substituted thiosemicarbazides with hydroxybenzaldehydes followed by the treatment with ethyl bromoacetate; maleic anhydride and dimethyl acetylenedicarboxylate afforded target compounds. The thiazolidin-4-one derivatives were used to assess the inhibition of Toxoplasma gondii growth in vitro. All active thiazolidine-4-one derivatives (12 compounds) inhibited T. gondii proliferation in vitro much better than used references drugs both sulfadiazine as well as the synergistic effect of sulfadiazine + trimethoprim (weight ratio 5:1). Most active among them derivatives 94 and 95 showed inhibition of proliferation at about 392-fold better than sulfadiazine and 18-fold better than sulfadiazine with trimethoprim. All active compounds (82\u201388 and 91\u201395) against T. gondii represent values from 1.75 to 15.86 (CC30\/IC50) lower than no cytotoxic value (CC30).<\/jats:p>","DOI":"10.3390\/molecules24173029","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T11:19:06Z","timestamp":1566386346000},"page":"3029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Synthesis and In Vitro Anti-Toxoplasma gondii Activity of Novel Thiazolidin-4-one Derivatives"],"prefix":"10.3390","volume":"24","author":[{"given":"Nazar","family":"Trotsko","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 4A Chod\u017aki, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-1074","authenticated-orcid":false,"given":"Adrian","family":"Bekier","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-7702","authenticated-orcid":false,"given":"Agata","family":"Paneth","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 4A Chod\u017aki, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1934","authenticated-orcid":false,"given":"Monika","family":"Wujec","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 4A Chod\u017aki, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Dzitko","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: From animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","article-title":"Ocular toxoplasmosis: Clinical features and prognosis of 154 patients","volume":"109","author":"Berendschot","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3201\/eid0911.030143","article-title":"Toxoplasma gondii and schizophrenia","volume":"9","author":"Torrey","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1542\/peds.113.6.1567","article-title":"Long-term ocular prognosis in 327 children with congenital toxoplasmosis","volume":"113","author":"Wallon","year":"2004","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1590\/S0074-02762002000400001","article-title":"Some aspects of protozoan infections in immunocompromised patients\u2013A Review","volume":"97","author":"Ferreira","year":"2002","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_6","first-page":"140","article-title":"Update on treatment of ocular toxoplasmosis","volume":"6","year":"2009","journal-title":"Int. J. Med. Sci."},{"key":"ref_7","first-page":"87","article-title":"Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection own observations","volume":"57","author":"Lipka","year":"2011","journal-title":"Parasitol. News"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.09.031","article-title":"5-Ene-4-thiazolidinones\u2014An efficient tool in medicinal chemistry","volume":"140","author":"Kaminskyy","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2016.02.030","article-title":"Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole\/pyrazoline-thiazolidine-based hybrids","volume":"113","author":"Havrylyuk","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/j.bmc.2015.03.071","article-title":"Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions","volume":"23","author":"Chadna","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2013.11.017","article-title":"4-Thiazolidinones: The advances continue","volume":"72","author":"Tripathi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.bmc.2013.01.029","article-title":"Thiazolidine-2,4-diones: Progress towards multifarious applications","volume":"21","author":"Jain","year":"2013","journal-title":"Bioorganic Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ejmech.2007.07.017","article-title":"4-Thiazolidinone\u2014A biologically active scaffold","volume":"43","author":"Verma","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.bmcl.2005.03.048","article-title":"Synthesis of thiosemicarbazone and 4-thiazolidinone derivatives and their in vitro anti-Toxoplasma gondii activity","volume":"15","author":"Tenorio","year":"2005","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.ejmech.2010.05.017","article-title":"Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles","volume":"45","author":"Liesen","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bmc.2007.09.025","article-title":"Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids","volume":"16","author":"Liesen","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14756366.2017.1387543","article-title":"Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives","volume":"33","author":"Trotsko","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jsps.2018.01.016","article-title":"Synthesis and antibacterial activity of new (2,4-dioxothiazolidin-5-yl\/ylidene) acetic acid derivatives with thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin moieties","volume":"26","author":"Trotsko","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Trotsko, N., Kosikowska, U., Paneth, A., Plech, T., Malm, A., and Wujec, M. (2018). Synthesis and antibacterial activity of new thiazolidine-2,4-dione-based chlorophenylthiosemicarbazone hybrids. Molecules, 23.","DOI":"10.3390\/molecules23051023"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.3390\/molecules19079926","article-title":"1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation","volume":"19","author":"Dzitko","year":"2014","journal-title":"Molecules"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Paneth, A., W\u0119gli\u0144ska, L., Bekier, A., Stefaniszyn, E., Wujec, M., Trotsko, N., and Dzitko, K. (2019). Systematic identification of thiosemicarbazides for inhibition of Toxoplasma gondii growth in vitro. Molecules, 24.","DOI":"10.3390\/molecules24030614"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Paneth, A., W\u0119gli\u0144ska, L., Bekier, A., Stefaniszyn, E., Wujec, M., Trotsko, N., Hawry\u0142, A., Hawry\u0142, M., and Dzitko, K. (2019). Discovery of potent and selective halogen-substituted imidazole-thiosemicarbazides for inhibition of Toxoplasma gondii growth in vitro via structure-based design. Molecules, 24.","DOI":"10.3390\/molecules24081618"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:12:42Z","timestamp":1760188362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":22,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["molecules24173029"],"URL":"https:\/\/doi.org\/10.3390\/molecules24173029","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]}}}